TNFR2 antagonistic antibody (anti-TNFR2) inhibit Tregs by targeting TNFR2 in vitro, and kill TNFR2-expressing tumor cells and Tregs in advanced Sézary syndrome (Torrey et al., 2019; Moatti et al., 2022). Here, TNFRSF1B is linked to Sezary syndrome.